NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $19.00 price target on the stock.

A number of other research firms also recently weighed in on NRXP. EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th.

NRx Pharmaceuticals Stock Up 4.0 %

NASDAQ:NRXP opened at $1.31 on Monday. The company has a market cap of $15.84 million, a P/E ratio of -0.61 and a beta of 1.27. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $7.33. The firm’s 50 day moving average is $1.39 and its two-hundred day moving average is $2.15.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.